Should you consider NASDAQ:CPRX for growth investing?

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is suited for growth investing. Investors should of course do their own research, but we spotted CATALYST PHARMACEUTICALS INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

What matters for growth investors.

• In terms of Return on Equity(ROE), CATALYST PHARMACEUTICALS INC is performing well, achieving a 21.61% ratio. This highlights the company's effective allocation of shareholder investments and signifies its commitment to maximizing returns.
• CATALYST PHARMACEUTICALS INC has consistently surpassed EPS estimates in the last 4 quarters, reflecting its strong financial performance and effective management. This trend suggests the company's ability to generate positive earnings surprises and drive shareholder value.
• The 1-year revenue growth of CATALYST PHARMACEUTICALS INC (32.13%) has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and expand its market share.
• With consistent quarter-to-quarter (Q2Q) revenue growth of 25.33%, CATALYST PHARMACEUTICALS INC exemplifies its ability to generate increased sales and revenue streams. This growth signifies the company's strong business performance and its potential for continued growth.
• CATALYST PHARMACEUTICALS INC has shown positive growth in its operating margin over the past year, indicating improved operational efficiency. This growth highlights the company's ability to effectively manage costs and maximize profitability.
• CATALYST PHARMACEUTICALS INC has shown positive growth in its free cash flow (FCF) over the past year, indicating improved cash generation and financial strength. This growth highlights the company's ability to effectively manage its cash flows and generate surplus funds.
• CATALYST PHARMACEUTICALS INC has demonstrated consistent growth in its earnings per share (EPS) from one quarter to another (Q2Q), with a 221.0% increase. This indicates improving financial performance and the company's effective management of its operations.
• Over the past 3 months, analysts have adjusted their EPS Estimate for CATALYST PHARMACEUTICALS INC with a 29.77% change. This highlights the evolving outlook on the company's EPS potential.
• The recent financial report of CATALYST PHARMACEUTICALS INC demonstrates a 221.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• The earnings per share (EPS) growth of CATALYST PHARMACEUTICALS INC are accelerating: the current Q2Q growth of 221.0% is above the previous year Q2Q growth of -245.0%. Earnings momentum and acceleration are key for high growth systems.

Zooming in on the fundamentals.

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

Taking everything into account, CPRX scores 8 out of 10 in our fundamental rating. CPRX was compared to 564 industry peers in the Biotechnology industry. CPRX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. These ratings could make CPRX a good candidate for value and growth and quality investing.

Our latest full fundamental report of CPRX contains the most current fundamental analsysis.

More ideas for growth investing can be found on ChartMill in our Lois Navellier screen.

Keep in mind

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.